

REPLACED BY
ART 34 AMDT

P A T E N T C L A I M S

1. Use of one or more synthetic CRH-R1 antagonists and /or CRH-R2 agonists for the treatment of an inflammatory disease or condition associated to activation, deactivation, differentiation and apoptosis of macrophages.
2. Use according to claim 1, wherein the one or more synthetic CRH-R1 antagonists and/or CRH-R2 agonists comprises antalarmin.
3. Use according to claim 1 or 2, wherein the inflammatory disease or condition is chronic inflammatory bowel disease, idiopathic inflammatory disorder, inflammatory disorders of connective tissues, inflammatory demyelinating polyneuropathies, inflammatory myopathies, inflammatory diseases of joints including bursitis, the fibromyalgia syndrome and inflammatory diseases of upper gastrointestinal tract.
- 15 4. Pharmaceutical composition comprising one or more synthetic CRH-R1 antagonists and /or CRH-R2 agonists.
5. Pharmaceutical composition according to claim 4, wherein the composition is formulated for local or systemic administration.
6. Pharmaceutical composition according to claim 4 or 5, 20 wherein the composition further comprises usual excipients such as diluents, fillers, binders, disintegrants, lubricants, conserving agents, flavourings and colourings.
7. Pharmaceutical composition according to any of the claims 4 to 6, wherein the formulation is formulated for oral, parenteral or 25 transdermal administration.
8. Pharmaceutical composition according to claim 7, wherein the composition is formulated as an injection liquid.
9. Pharmaceutical composition according to any of the claims 30 claim 4 to 8, wherein the one or more synthetic CRH-R1 antagonist and/or CRH-R2 agonist comprises antalarmin.

10. Pharmaceutical composition according to claim 9, wherein the one or more synthetic CRH-R1 antagonist and/or CRH-R2 agonist is antalarmin.

11. Use of one or more synthetic CRH-R1 antagonists and /or 5 CRH-R2 agonists for the manufacture of a pharmaceutical composition for the treatment of an inflammatory disease or condition associated to activation, deactivation, differentiation and apoptosis of macrophages.

12. Use according to claim 11, wherein the inflammatory disease or condition is chronic inflammatory bowel disease, idiopathic 10 inflammatory disorder, inflammatory disorders of connective tissues, inflammatory demyelinating polyneuropathies, inflammatory myopathies, inflammatory diseases of joints including bursitis, the fibromyalgia syndrome and inflammatory diseases of upper gastrointestinal tract.

13. Kit intended for the treatment of an inflammatory disease or 15 condition comprising one or more CRH-R1 antagonists and /or CRH-R2 agonists comprised in one of more individual pharmaceutical compositions.

14. Kit according to claim 13, wherein the one or more CRH-R1 antagonists and/or CRH-R2 agonists comprises antalarmin.